Washington, D.C. – Today, Colorado U.S. Senator Michael Bennet applauded inclusion of his Verifying Accurate Leading-Edge IVCT Development (VALID) Act in the discussion draft of the Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act that the U.S. Senate Health, Education, Labor and Pensions (HELP) Committee leadership released today. The bill will reauthorize the U.S. Food and Drug Administration’s (FDA) user fee programs.
“After years of working with late Senator Hatch and Senator Burr to pass diagnostic regulatory reform, I’m pleased to see a version of our bipartisan VALID Act included in the Senate FDA User Fees reauthorization discussion draft,” said Bennet. “Accurate and high-quality diagnostic tests are absolutely critical to public health and patient care, as demonstrated by the reliance on tests during the COVID-19 pandemic. I look forward to working with the committee on a path forward to best protect patients and support innovation.”
In 2018, Bennet introduced a version of the VALID Act with Senator Orrin Hatch (R-Utah). Bennet recently introduced the VALID Act in June 2021 with U.S. Senator Richard Burr (R-N.C.). The legislation would establish a new regulatory framework for the review and approval of diagnostic tests to accelerate innovation, protect public health, and ensure Americans can rely on the test results they receive.